CVS Health Co. (NYSE: CVS – Get Rating) – Investment analysts at Jefferies Financial Group issued their Q2 2022 earnings per share (EPS) estimates for shares of CVS Health in a research report issued on Sunday, June 19th. Jefferies Financial Group analyst B. Tanquilut anticipates that the pharmacy operator will post earnings of $ 2.18 per share for the quarter. The consensus estimate for CVS Health’s current full-year earnings is $ 8.33 per share. Jefferies Financial Group also issued estimates for CVS Health’s Q3 2022 earnings at $ 2.08 EPS, Q4 2022 earnings at $ 1.88 EPS and FY2023 earnings at $ 8.98 EPS.
CVS Health (NYSE: CVS – Get Rating) last issued its quarterly earnings results on Wednesday, May 4th. The pharmacy operator reported $ 2.22 earnings per share for the quarter, topping the consensus estimate of $ 2.14 by $ 0.08. The company had revenue of $ 76.83 billion for the quarter, compared to analysts’ expectations of $ 75.30 billion. CVS Health had a return on equity of 15.33% and a net margin of 2.67%. The firm’s revenue for the quarter was up 11.2% on a year-over-year basis. During the same period in the prior year, the firm earned $ 2.04 earnings per share.
Several other equities research analysts also recently commented on CVS. Tigress Financial boosted their target price on CVS Health from $ 122.00 to $ 125.00 in a report on Thursday, April 7th. Deutsche Bank Aktiengesellschaft upped their price target on CVS Health from $ 110.00 to $ 113.00 in a research report on Thursday, May 5th. Loop Capital initiated coverage on CVS Health in a research report on Thursday, June 16th. They issued a “buy” rating and a $ 120.00 price target for the company. StockNews.com initiated coverage on CVS Health in a research report on Thursday, March 31st. They issued a “strong-buy” rating for the company. Finally, Sanford C. Bernstein cut CVS Health from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $ 122.00 to $ 112.00 in a research report on Thursday, May 26th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $ 116.05.
CVS Health stock opened at $ 91.08 on Tuesday. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 0.70. The business’s fifty day simple moving average is $ 97.35 and its two-hundred day simple moving average is $ 101.49. CVS Health has a 12 month low of $ 79.33 and a 12 month high of $ 111.25. The company has a market capitalization of $ 119.43 billion, a price-to-earnings ratio of 15.13, a price-to-earnings-growth ratio of 1.40 and a beta of 0.78.
In other CVS Health news, EVP Daniel P. Finke sold 55,359 shares of the firm’s stock in a transaction on Monday, April 4th. The stock was sold at an average price of $ 100.13, for a total transaction of $ 5,543,096.67. Following the transaction, the executive vice president now directly owns 3,098 shares in the company, valued at approximately $ 310,202.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Prem S. Shah sold 16,954 shares of the firm’s stock in a transaction on Friday, April 8th. The stock was sold at an average price of $ 105.00, for a total value of $ 1,780,170.00. Following the transaction, the executive vice president now owns 43,453 shares in the company, valued at $ 4,562,565. The disclosure for this sale can be found here. Insiders have sold a total of 77,659 shares of company stock valued at $ 7,882,993 over the last three months. 0.69% of the stock is owned by corporate insiders.
Several large investors have recently made changes to their positions in the company. Griffin Asset Management Inc. boosted its position in shares of CVS Health by 0.5% in the 4th quarter. Griffin Asset Management Inc. now owns 21,187 shares of the pharmacy operator’s stock worth $ 2,186,000 after purchasing an additional 95 shares in the last quarter. Townsend Asset Management Corp NC ADV boosted its position in shares of CVS Health by 0.6% in the 4th quarter. Townsend Asset Management Corp NC ADV now owns 17,344 shares of the pharmacy operator’s stock worth $ 1,789,000 after purchasing an additional 96 shares in the last quarter. Garrett Investment Advisors LLC boosted its position in shares of CVS Health by 1.5% in the 4th quarter. Garrett Investment Advisors LLC now owns 6,831 shares of the pharmacy operator’s stock worth $ 705,000 after purchasing an additional 98 shares in the last quarter. First Bancorp Inc ME boosted its position in shares of CVS Health by 2.8% in the 4th quarter. First Bancorp Inc ME now owns 3,590 shares of the pharmacy operator’s stock worth $ 371,000 after purchasing an additional 98 shares in the last quarter. Finally, Gryphon Financial Partners LLC boosted its position in shares of CVS Health by 2.0% in the 4th quarter. Gryphon Financial Partners LLC now owns 5,084 shares of the pharmacy operator’s stock worth $ 525,000 after purchasing an additional 99 shares in the last quarter. Institutional investors and hedge funds own 78.00% of the company stock.
CVS Health Company Profile: (Get Rating)
CVS Health Corporation provides health services in the United States. The company Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, government units, government-sponsored plans, labor groups, and expatriates.
See Also:
Receive News & Ratings for CVS Health Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CVS Health and related companies with MarketBeat.com’s FREE daily email newsletter.
.